Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Vipadenant

Home DrugsVipadenant

Investigational

Small Molecule

Vipadenant

Unknown Manufacturer

Generate AI report

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Indications

Investigated for use/treatment in parkinson's disease.

Technical identifiers

Chemical Formula: C₁₆H₁₅N₇O
CAS Number: 442908-10-3
UNII ID: LDR3USH1NJ

Patents

One entry per invention. Patent families filed in the US, EP, WO and CN offices.

EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES (TILS) WITH ADENOSINE A2A RECEPTOR ANTAGONISTS AND THERAPEUTIC COMBINATIONS OF TILS AND ADENOSINE A2A RECEPTOR ANTAGONISTS
EP 3752600 A1Applicant: IOVANCE BIOTHERAPEUTICS INCPriority: 2018
EP
US
WO
3 publications
ADENOSINE A2A RECEPTOR ANTAGONISTS TO TREAT REM SLEEP BEHAVIOR DISORDER AND PREVENT SYNUCLEINOPATHIES
WO 2025221958 A1Applicant: CORVUS PHARMACEUTICALS INCPriority: 2024
WO